One of the earliest and most profound insights into the pathophysiology of COVID-19 disease was that of it’s extreme “hypercoagulability” found the most severely ill patients suffering severe inflammation. The studies below detail both the high incidences and types of clotting complications seen in critically ill COVOD-19 patients along with studies demonstrating associations between anti-coagulant treatment and improvements in survival.
“Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia”
“Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19”
“High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study”
“Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19”
“Incidence of venous thromboembolism in hospitalized patients with COVID‐19”
“Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy”